Beyond the Basics – Lower-Risk Myelodysplastic Syndromes
Saeed Sadeghi, MD, discusses a case of lower-risk myelodysplastic syndromes (LR-MDS), focusing on the mechanisms of action for luspatercept vs epoetin alfa, insights from the COMMANDS study, real-world data on treatment outcomes, health care resource utilization, and future directions in anemia management within this patient population.
EP. 1: Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS
September 30th 2024Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these differences may correlate with clinical benefits for patients with lower-risk myelodysplastic syndromes (LR-MDS).
Watch
EP. 2: COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment
October 7th 2024Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of outcome data comparing luspatercept to epoetin alfa in first-line (1L) treatment for lower-risk myelodysplastic syndromes (LR-MDS).
Watch
